GENE ONLINE|News &
Opinion
Blog

Donanemab
FDA Grants Breakthrough Status to Two Experimental Alzheimer’s Drugs While Pushback Over Aduhelm’s Approval Still Rages On
2021-06-25
Lilly’s Positive Data for Alzheimer’s Drug Bodes Well for Candidates Rooted in Amyloid Hypothesis
2021-03-14
Lilly’s Donanemab Aces Phase 2 Trial, Slows Clinical Decline in Alzheimer’s Patients
2021-01-15
Top Announcements from the J.P. Morgan Healthcare Conference 2021
2021-01-13
LATEST
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Scroll to Top